ContractSub-Licence and Collaboration Agreement • September 3rd, 2019 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances) • New York
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
AMENDMENT 4 TO SUB-LICENCE AND COLLABORATION AGREEMENTSub-Licence and Collaboration Agreement • August 7th, 2019 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances)
This Fourth Amendment (the “Amendment”) to the Sub-Licence and Collaboration Agreement dated 20 March 2012, as amended (the “2012 Agreement”) is entered into and effective as of the last date of signature (the “Amendment Effective Date”), by and between:
AMENDMENT NO. 3 TO SUB-LICENCE AND COLLABORATION AGREEMENTSub-Licence and Collaboration Agreement • August 7th, 2019 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances)
This Amendment No. 3 to Sub-Licence and Collaboration Agreement (“Amendment No.3”) is effective as of 31 December 2015 (the “Amendment No.3 Effective Date”) by and between MedImmune, LLC, a Delaware limited liability company with a place of business at One MedImmune Way, Gaithersburg, MD20878, United States (“MedImmune”) and Humabs BioMed SA, a limited company organized under the laws of Switzerland having its head office at Via Mirasloe 1, Bellinzona CH-6500, Switzerland ( “Humabs”). MedImmune and Humabs are each referred to herein as a “Party” and collectively as the “Parties”.
AMENDMENT 2 TO SUB-LICENCE AND COLLABORATION AGREEMENTSub-Licence and Collaboration Agreement • September 3rd, 2019 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances)
This Amendment (the “Amendment”) to the Sub-License and Collaboration Agreement dated March 20, 2012 (“Agreement”) is entered into effective as of the last date of signature (the “Amendment Effective Date”), by and between MedImmune, LLC, a Delaware limited liability company, with its principal executive offices located at One MedImmune Way, Gaithersburg, MD 20878 (“MedImmune”) and Humabs BioMed SA. a limited company organized under the laws of Switzerland having its head office at Via Mirasloe 1, bellinzona CH-6500 Switzerland (“Humabs”).
